Traders should monitor upcoming top-line Phase 3 data in Q3 2026 as the primary catalyst; current losses are expected due to trial costs, but a positive readout could significantly revalue the stock given the unmet medical need in NPC1.
Price Chart
Executive Summary
Rafael Holdings reported Q2 FY2026 financial results with a net loss of $6.4 million, wider than the prior year's $4.6 million loss, driven by increased R&D expenses from the Cyclo Therapeutics acquisition. Despite higher losses, cash remains strong at $37.8 million, and the company continues to advance its pivotal Phase 3 trial for Trappsol® Cyclo™ in Niemann-Pick Disease Type C1, with top-line results expected in Q3 2026.
Key Financial Metrics
Key Facts
- Net loss for Q2 FY2026 was $6.4 million ($0.13/share), up from $4.6 million ($0.19/share) in the year-ago period.
- R&D expenses rose to $4.5 million from $0.9 million due to consolidation of Cyclo Therapeutics post-acquisition in March 2025.
- Cash and cash equivalents were $37.8 million as of January 31, 2026, down from $52.8 million at the start of the fiscal year.
- Pivotal Phase 3 TransportNPC™ trial for Trappsol® Cyclo™ remains on track, with top-line results expected in Q3 2026.
- Total revenue increased to $211K from $77K, primarily due to new product revenue of $125K.
Financial Impact
Increased R&D spend added ~$3.6M in costs; product revenue contributed $125K. Net loss widened by $1.8M YoY.
Risk Factors
- Clinical trial failure risk for Trappsol® Cyclo™ in Phase 3 could lead to sharp downside.
- Continued cash burn may necessitate future dilution if no near-term commercial path or partnership emerges.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256686 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 27d ago | 8-K | $1.32 | awaiting T+20 | — | $1.29 (−2.27%) |
Sep 30, 2026 27d ago | Press Release | $1.32 | awaiting T+20 | — | $1.29 (−2.27%) |
Aug 18, 2026 10w ago | Institutional Cluster | $1.86 $2.10 | ▲ +12.90% | ▲ +13.89% | $1.29 (−30.65%) |
Jun 11, 2026 19w ago | 8-K | $2.12 $2.27 | ▲ +7.08% | ▲ +5.18% | $1.29 (−39.15%) |
Jun 10, 2026 19w ago | 8-K | $1.78 $2.27 | ▲ +27.53% | ▲ +23.91% | $1.29 (−27.53%) |
Jun 10, 2026 19w ago | Press Release | $1.78 $2.27 | ▲ +27.53% | ▲ +23.91% | $1.29 (−27.53%) |
Apr 22, 2026 26w ago | 8-K | $1.30 $1.35 | ▲ +3.85% | ▲ +0.68% | $1.29 (−0.77%) |
Mar 16, 2026 32w ago | Press Release | $1.32 $1.22 | ▼ −7.58% | ▼ −11.88% | $1.29 (−2.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers